HMGB1/RAGE Signaling and Pro-Inflammatory Cytokine Responses in Non-HIV Adults with Active Pulmonary Tuberculosis

Background We aimed to study the pathogenic roles of High-Mobility Group Box 1 (HMGB1) / Receptor-for-Advanced-Glycation-End-products (RAGE) signaling and pro-inflammatory cytokines in patients with active pulmonary tuberculosis (PTB). Methods A prospective study was conducted among non-HIV adults newly-diagnosed with active PTB at two acute-care hospitals (n = 80); age-and-sex matched asymptomatic individuals (tested for latent TB) were used for comparison (n = 45). Plasma concentrations of 8 cytokines/chemokines, HMGB1, soluble-RAGE, and transmembrane-RAGE expressed on monocytes/dendritic cells, were measured. Gene expression (mRNA) of HMGB1, RAGE, and inflammasome-NALP3 was quantified. Patients’ PBMCs were stimulated with recombinant-HMGB1 and MTB-antigen (lipoarabinomannan) for cytokine induction ex vivo. Results In active PTB, plasma IL-8/CXCL8 [median(IQR), 6.0(3.6–15.1) vs 3.6(3.6–3.6) pg/ml, P<0.001] and IL-6 were elevated, which significantly correlated with mycobacterial load, extent of lung consolidation (rs +0.509, P<0.001), severity-score (rs +0.317, P = 0.004), and fever and hospitalization durations (rs +0.407, P<0.001). IL-18 and sTNFR1 also increased. Plasma IL-8/CXCL8 (adjusted OR 1.12, 95%CI 1.02–1.23 per unit increase, P = 0.021) and HMGB1 (adjusted OR 1.42 per unit increase, 95%CI 1.08–1.87, P = 0.012) concentrations were independent predictors for respiratory failure, as well as for ICU admission/death. Gene expression of HMGB1, RAGE, and inflammasome-NALP3 were upregulated (1.2−2.8 fold). Transmembrane-RAGE was increased, whereas the decoy soluble-RAGE was significantly depleted. RAGE and HMGB1 gene expressions positively correlated with cytokine levels (IL-8/CXCL8, IL-6, sTNFR1) and clinico-/radiographical severity (e.g. extent of consolidation rs +0.240, P = 0.034). Ex vivo, recombinant-HMGB1 potentiated cytokine release (e.g. TNF-α) when combined with lipoarabinomannan. Conclusion In patients with active PTB, HMGB1/RAGE signaling and pro-inflammatory cytokines may play important roles in pathogenesis and disease manifestations. Our clinico-immunological data can provide basis for the development of new strategies for disease monitoring, management and control.

[1]  P. Tiwari,et al.  Establishment of Elevated Serum Levels of IL-10, IL-8 and TNF-β as Potential Peripheral Blood Biomarkers in Tubercular Lymphadenitis: A Prospective Observational Cohort Study , 2016, PloS one.

[2]  L. Bi,et al.  Cytokine and Antibody Based Diagnostic Algorithms for Sputum Culture-Positive Pulmonary Tuberculosis , 2015, PloS one.

[3]  J. Dziadek,et al.  Binding of CXCL8/IL-8 to Mycobacterium tuberculosis Modulates the Innate Immune Response , 2015, Mediators of inflammation.

[4]  R. Hernández-Pando,et al.  The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis , 2015, PloS one.

[5]  Peter A Keyel,et al.  How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. , 2014, Cytokine.

[6]  T. Morishima,et al.  High mobility group box 1 in patients with 2009 pandemic H1N1 influenza-associated encephalopathy , 2014, Brain and Development.

[7]  R. Basaraba,et al.  High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines , 2014, Immunology.

[8]  P. Nieminen,et al.  Soluble receptor for advanced glycation end-products and progression of airway disease , 2014, BMC Pulmonary Medicine.

[9]  B. Alisjahbana,et al.  Early clearance of Mycobacterium tuberculosis: a new frontier in prevention , 2014, Immunology.

[10]  G. Lui,et al.  High Mortality in Adults Hospitalized for Active Tuberculosis in a Low HIV Prevalence Setting , 2014, PloS one.

[11]  Yan-ting Zhu,et al.  Activation of PPARγ attenuates LPS-induced acute lung injury by inhibition of HMGB1-RAGE levels. , 2014, European journal of pharmacology.

[12]  D. Musumeci,et al.  An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies. , 2014, Pharmacology & therapeutics.

[13]  A. Norrby-Teglund,et al.  HMGB1 in severe soft tissue infections caused by Streptococcus pyogenes , 2014, Front. Cell. Infect. Microbiol..

[14]  S. Wong,et al.  Role of human Toll‐like receptors in naturally occurring influenza A infections , 2013, Influenza and other respiratory viruses.

[15]  M. Rottenberg,et al.  Expression of M. tuberculosis-induced suppressor of cytokine signaling (SOCS) 1, SOCS3, FoxP3 and secretion of IL-6 associates with differing clinical severity of tuberculosis , 2013, BMC Infectious Diseases.

[16]  J. Milanowski,et al.  Evaluation of High-Mobility Group Box 1 Protein Concentration in Serum of Patients with M. tuberculosis Infection , 2013, Immunological investigations.

[17]  T. van der Poll,et al.  Receptor for advanced glycation end products is protective during murine tuberculosis. , 2012, Molecular immunology.

[18]  D. Baarle,et al.  Analysis of immune responses against a wide range of Mycobacterium tuberculosis antigens in 1 active pulmonary tuberculosis patients 2 3 , 2012 .

[19]  N. Zhao,et al.  Host gene-encoded severe lung TB: from genes to potential pathways , 2012, Genes and Immunity.

[20]  W. Sadee,et al.  Innate Immune Gene Polymorphisms in Tuberculosis , 2012, Infection and Immunity.

[21]  J. Tschopp,et al.  Activation of the NLRP3 inflammasome by Mycobacterium tuberculosis is uncoupled from susceptibility to active tuberculosis , 2012, European journal of immunology.

[22]  D. Hui,et al.  Cytokine Response Patterns in Severe Pandemic 2009 H1N1 and Seasonal Influenza among Hospitalized Adults , 2011, PloS one.

[23]  O. Bottasso,et al.  A Multifaceted Analysis of Immune-Endocrine-Metabolic Alterations in Patients with Pulmonary Tuberculosis , 2011, PloS one.

[24]  L. Wood,et al.  Soluble RAGE is deficient in neutrophilic asthma and COPD , 2011, European Respiratory Journal.

[25]  D. Hui,et al.  Interferon gamma release assay for differentiating tuberculosis among pneumonia cases in acute healthcare setting. , 2011, The Journal of infection.

[26]  J. Sung,et al.  Viral Clearance and Inflammatory Response Patterns in Adults Hospitalized for Pandemic 2009 Influenza A(H1N1) Virus Pneumonia , 2011, Antiviral therapy.

[27]  K. Tracey,et al.  Inflammasome-Dependent Release of the Alarmin HMGB1 in Endotoxemia , 2010, The Journal of Immunology.

[28]  Paul M Kelly,et al.  A simple, valid, numerical score for grading chest x-ray severity in adult smear-positive pulmonary tuberculosis , 2010, Thorax.

[29]  K. Dheda,et al.  The immunology of tuberculosis: From bench to bedside , 2010, Respirology.

[30]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[31]  A. Castiglioni,et al.  High-mobility group box 1 (HMGB1) as a master regulator of innate immunity , 2010, Cell and Tissue Research.

[32]  H. Dockrell,et al.  CCL2 Responses to Mycobacterium tuberculosis Are Associated with Disease Severity in Tuberculosis , 2009, PloS one.

[33]  M. Huang,et al.  NLRP3 (NALP3, Cryopyrin) Facilitates In Vivo Caspase-1 Activation, Necrosis, and HMGB1 Release via Inflammasome-Dependent and -Independent Pathways1 , 2009, The Journal of Immunology.

[34]  K. Boda,et al.  Plasma Concentrations of High-Mobility Group Box Protein 1, Soluble Receptor for Advanced Glycation End-Products and Circulating DNA in Patients with Acute Pancreatitis , 2009, Pancreatology.

[35]  M. Sodemann,et al.  Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. , 2009, American journal of respiratory and critical care medicine.

[36]  F. Santilli,et al.  Soluble forms of RAGE in human diseases: clinical and therapeutical implications. , 2009, Current medicinal chemistry.

[37]  A. Izzo,et al.  Mycobacterial infection induces the secretion of high‐mobility group box 1 protein , 2008, Cellular microbiology.

[38]  K. Medzihradszky,et al.  High Mobility Group Box 1 Protein Induction by Mycobacterium Bovis BCG , 2007, Mediators of inflammation.

[39]  John L. Johnson,et al.  Cavitary Disease and Quantitative Sputum Bacillary Load in Cases of Pulmonary Tuberculosis , 2007, Journal of Clinical Microbiology.

[40]  J. Sung,et al.  Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  L. Audoly,et al.  Toll-like receptor 9–dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE , 2007, Nature Immunology.

[42]  D. Angus,et al.  Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis* , 2007, Critical care medicine.

[43]  K. Tracey,et al.  High mobility group box‐1 protein induces the migration and activation of human dendritic cells and acts as an alarmin , 2007, Journal of leukocyte biology.

[44]  M. Teixeira,et al.  Concentrations of CXCL8, CXCL9 and sTNFR1 in plasma of patients with pulmonary tuberculosis undergoing treatment , 2006, Inflammation Research.

[45]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[46]  G. Diette,et al.  Hospitalizations for tuberculosis in the United States in 2000: predictors of in-hospital mortality. , 2004, Chest.

[47]  J. Musser,et al.  Association between interleukin-8 gene alleles and human susceptibility to tuberculosis disease. , 2003, The Journal of infectious diseases.

[48]  S. Kaufmann,et al.  How can immunology contribute to the control of tuberculosis? , 2001, Nature Reviews Immunology.

[49]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.